Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
Last trade$0.5764
Day change-$0.0337 (-5.52%)
Day range$0.566 – $0.635
Volume907,325
Market cap$65M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$64.78M
Price / earnings
—
Price / book
2.04×
Price / sales
3.4×
EV / sales
2.11×
EV / EBITDA
-1.3×
Profitability
Earnings per share
-$0.28
Return on assets
-51.59%
Return on equity
-93.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.42×
Current ratio
5.1×
Quick ratio
4.5×
Cash ratio
3.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.92M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HYPR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$5.96M
$3.9M
$3.9M
$5.29M
$3.44M
$2.7M
$2.14M
$2.32M
Cost of revenue
$2.58M
$1.92M
$1.92M
$2.6M
$1.59M
$1.37M
$1.25M
$1.5M
Gross profit
$3.38M
$1.98M
$1.98M
$2.69M
$1.85M
$1.33M
$883K
$826K
Selling, general and administrative
$6.73M
$6.58M
$6.69M
$6.54M
$6.72M
$6.38M
$6.75M
$6.49M
Research and development
$3.91M
$3.87M
$3.85M
$3.83M
$4.05M
$4.54M
$5.04M
$5.11M
Total operating expenses
$10.64M
$10.45M
$10.54M
$10.36M
$10.77M
$10.92M
$11.79M
$11.59M
Operating income
-$7.26M
-$8.47M
-$8.56M
-$7.67M
-$8.92M
-$9.6M
-$10.9M
-$10.77M
Interest expense
-$549K
-$533K
-$83K
$0
$0
$0
$0
$0
Income before taxes
-$5.98M
-$9.3M
-$8.62M
-$5.91M
-$11.02M
-$9.23M
-$9.42M
-$10.39M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.98M
-$9.3M
-$8.62M
-$5.91M
-$11.02M
-$9.23M
-$9.42M
-$10.39M
Net income attributable to common shareholders
-$5.98M
-$9.3M
-$8.62M
-$5.91M
-$11.02M
-$9.23M
-$9.42M
-$10.39M
EBITDA
-$7.01M
-$8.21M
-$8.28M
-$7.39M
-$8.62M
-$9.31M
-$10.67M
-$10.53M
Basic earnings per share
-$0.06
-$0.09
-$0.09
-$0.06
-$0.14
-$0.12
-$0.12
-$0.14
Diluted earnings per share
-$0.06
-$0.09
-$0.09
-$0.06
-$0.14
-$0.12
-$0.12
-$0.14
Recent news
Company coverage with links to the original publishers.
Five companies—VentriPoint Diagnostics, HeartBeam, Heartflow, Hyperfine, and GE Healthcare Technologies—are advancing AI-enabled cardiac diagnostic platforms to address the global heart disease crisis. Recent developments include VentriPoint's partnership with First Light Health for remote Indigenous communities, HeartBeam's collaboration with Mount Sinai on AI-ECG algorithms, Heartflow's new clinical registry data, Hyperfine's breakthrough stroke detection results, and GE Healthcare's role in the EU's COMPASS cardiotoxicity initiative.
AI-driven clinical intelligence is transforming medical imaging, with point-of-care diagnostics projected to reach $70.92 billion by 2032. The CMS ACCESS Model launching in July 2026 will reward outcome-based care, driving adoption of software-defined imaging platforms. Key players including VentriPoint Diagnostics, Butterfly Network, Hyperfine, Hologic, and GE HealthCare are advancing portable, AI-powered diagnostic solutions that deliver hospital-grade precision at the bedside, reducing facility overhead while improving patient outcomes.
Hyperfine reported Q2 2025 results with $2.7 million revenue, 26% sequential increase, and eight system sales. The company achieved FDA clearances, expanded gross margins to 49.3%, and reduced cash burn by 19%, projecting 10-20% revenue growth for the year.
Hyperfine's Swoop system has shown promising results in a study on its ability to quickly assess stroke patients and guide treatment decisions. The study, part of the larger ACTION PMR study, found the Swoop system to be a reliable tool for enabling critical stroke treatment choices in urgent care settings.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.